Basel, September 2, 2014 – Janko Ignjatovic of Serbia has been selected as one of three individual winners of the Novartis International BioCamp held in Basel last week. Mr. Ignjatovic, who studies pharmacy at the University of Belgrade, came to the event through the Regional BioCamp, which took place in June and was organized by Lek, a Sandoz company.

 

Mr. Ignjatovic proved to be the best at combining a scientific and business solution in his case study at the Regional BioCamp in Slovenia, which is what promoted him to participate in the Novartis BioCamp. …

August 29, 2014 – Novartis has a strong history of CR activities, and transparent reporting is a central part of our commitment to corporate responsibility. We have publicly reported on our performance in this area since 2000 through our Annual Report and several online and printed materials.

For 2013, we have consolidated information previously published in our separate GRI; Health, Safety and Environment; and United Nations Global Compact reports into a single Corporate Responsibility Performance Report.

This report enhances our transparency in several key …

August 21, 2014 – Life-saving medicines from Sandoz have arrived at the University Teaching Hospital in Lusaka, Zambia. The donated units of benzathine penicillin will support a new rheumatic heart disease study by the Novartis Institutes for BioMedical Research (NIBR). Penicillin prophylaxis is the only way by which new cases of rheumatic heart disease can be prevented.

Rheumatic heart disease (RHD) has been practically eradicated in wealthy nations, but in the developing world the disease remains a major cause of morbidity and mortality, particularly in children …

• Sandoz Germany launches Vitaros®, an innovative new patent-protected therapy for leading urology disorder erectile dysfunction (ED)
• First topical therapy approved for treatment of ED, characterized by ease of use, rapid onset and high tolerability
• Launch in Sandoz’s largest EU market further demonstrates company commitment to meeting unmet medical need across key therapeutic areas

Holzkirchen, August 18, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in Germany of Vitaros®, an innovative new …

• Sandoz is the first company to announce it has filed for approval of a biologic under the biosimilars pathway created in the Biologics Price Competition and Innovation Act of 2009 (BPCIA)
• FDA’s acceptance of Sandoz’s filing is an important first step in increasing US patient access to affordable, high-quality biologics
• Sandoz is a global leader in biosimilars with over 50% share of the global biosimilars market1

Holzkirchen, July 24, 2014 – Sandoz, a Novartis Group company, announced today that the US Food and Drug Administration (FDA) has …